NGF and myeloid sarcoma: NGF also down-regulates the co-stimulatory molecules CD40 and CD86 in microglia (Wei and Jonakait, 1999), is increased in cerebral spinal fluid of MS patients (Laudiero et al., 1992), and NGF treatment delays EAE onset and clinical severity (Arredondo et al., 2001).